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In vivo label-free photoacoustic 
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Metastasis causes as many as 90% of cancer-related deaths, especially for the deadliest skin cancer, 
melanoma. Since hematogenous dissemination of circulating tumor cells is the major route of 
metastasis, detection and destruction of circulating tumor cells are vital for impeding metastasis and 
improving patient prognosis. Exploiting the exquisite intrinsic optical absorption contrast of circulating 
melanoma cells, we developed dual-wavelength photoacoustic flow cytography coupled with a 
nanosecond-pulsed melanoma-specific laser therapy mechanism. We have successfully achieved in vivo 
label-free imaging of rare single circulating melanoma cells in both arteries and veins of mice. Further, 
the photoacoustic signal from a circulating melanoma cell immediately hardware-triggers a lethal 
pinpoint laser irradiation to kill it on the spot in a thermally confined manner without causing collateral 
damage. A pseudo-therapy study including both in vivo and in vitro experiments demonstrated the 
performance and the potential clinical value of our method, which can facilitate early treatment of 
metastasis by clearing circulating tumor cells from vasculature.
As many as 90% of cancer-related deaths are attributed to metastases, mostly taking the route of hematoge-
nous dissemination of circulating tumor cells (CTCs)1–4. Melanoma has a high propensity for metastasis even 
at an early stage5,6, therefore early detection and treatment of melanoma CTCs are vital for reducing the risks 
of metastasis and improving patient prognosis4,7. Clinical ex vivo CTC detection with high sensitivity remains 
a challenge since it heavily depends on both small-volume sampling of blood and labeling of biomarkers on 
the cell membrane3,4,8,9. Extensive in vivo CTC detection studies employing fluorescence probes9,10 or multiplex 
nanoparticles11,12 have achieved promising results, but the biosafety and labeling efficiency remain critical 
concerns, which limits their clinical translation. Compared to other biological tissue components, melanoma 
cells have a high melanosome expression, providing a striking endogenous absorption contrast in the red to 
near-infrared (NIR) spectrum13,14. Hence, photoacoustic (PA) imaging, having the highest possible sensitivity to 
absorption contrast15–17, is a perfect tool for label-free imaging of melanoma cells17–19. In 2009, Galanzha et al. 
reported label-free detection of melanoma CTCs in vivo using PA cytometry12, in which a pulsed laser was focused 
across a blood vessel and an ultrasonic transducer collected PA signals from a large voxel. This design enables 
detection of melanoma CTCs in situ, but it lacks imaging capabilities. A recently developed optical-resolution PA 
imaging technique has acquired images of single CTCs in vivo18. However its non-optic-acoustic-confocal config-
uration and low CTC-to-background contrast limit the applications to capillaries and require complicated pattern 
recognition to identify CTCs18. High-contrast flow cytography that can reliably distinguish CTCs in real-time is 
needed for on-the-fly targeted CTC therapies.
Traditional clinical therapies for tumor metastasis are still palliative, with many drugs not reaching metasta-
sis sites2,20. Novel therapies based on particular metastasis features, such as angiogenesis, lymphangiogenesis21, 
specific signal pathways and biomarkers20, have reported good clinical outcome, but they have less efficacy on 
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initial micro-metastasis sites and typically produce adverse side effects22,23. Taking another approach, therapies 
directly targeting CTCs can reduce tumor metastasis potentials and may even prevent metastasis from occurring 
if administered in early tumor stages4,7. Nanosecond-pulsed lasers at 680–1064 nm wavelengths have long ena-
bled physicians to treat melanocytic skin lesions with a high degree of selectivity and a low risk of postoperative 
complications24,25. For laser pulses shorter than the thermal relaxation time, radiant energy is largely confined in 
the absorber26, which can achieve efficient energy delivery and selective photothermolysis of the absorbing cells27. 
When a nanosecond laser pulse with sufficient energy irradiates a melanoma CTC, the melanosomes inside are 
heated beyond the threshold temperature for explosive vaporization, photomechanically killing the CTC without 
damaging any adjacent tissue components26,27.
Here we report high-resolution CTC imaging, using our new dual-wavelength PA flow cytography technology, 
in combination with real-time CTC destruction at the single-cell scale by pinpoint nanosecond-pulsed lethal irra-
diation from a therapy laser. We obtained images of single CTCs flowing in both arteries and veins on the fly, and 
performed real-time CTC destruction in vivo in small animals. The performance of this system was demonstrated 
by a study mimicking treatment of melanoma metastasis.
Results
Imaging results. To exploit the NIR absorption contrast between melanosome and hemoglobin (Hb) in red 
blood cells (RBCs), and to image CTCs on the fly, we developed a fast scanning PA flow cytography system for 
high-speed imaging at both 532 nm and 1064 nm wavelengths with single-cell resolution coupled with real-time 
selective CTC destruction by nanosecond-pulsed NIR laser-induced photothermolysis (Fig. 1, Methods). The 
therapy laser beam is coaxially aligned with the two imaging laser beams, and is triggered, using real-time hard-
ware, immediately after flow cytography detects a CTC (Fig. 1b–e, Supplementary Fig. S1). We first validated the 
system’s ability to image single CTCs with the therapy laser turned off. To simulate CTCs, ~106 cultured B16F10 
melanoma cells were administrated into the mouse’s blood circulation system through jugular vein cannulation, 
and a portion of these cells survived in circulation as CTCs. A 1.2 × 0.3 mm2 area of an artery-vein pair in the 
mouse ear was imaged by flow cytography at a 16.6 Hz volumetric (3D) rate. Figure 2 shows some snapshots of 
single CTCs flowing through the field of view (FOV) in the artery and the vein, and Supplementary Movie S1 
shows the entire time course. As shown in Fig. 2a, the vascular structure was imaged with high contrast by the 
532 nm laser owing to the strong light absorption by Hb in RBCs at this wavelength. However, CTCs can hardly 
be distinguished from RBCs in these images, mainly due to the similar absorption coefficients for melanosome 
and Hb at 532 nm. In comparison, the 1064 nm laser pulse excitation of a CTC produced a PA signal with ~5 
times greater amplitude than the background, while RBC signals were below the noise level. We performed con-
trol studies for 20 minutes before cell injection and recorded no PA signals of a similar amplitude level, which 
verified that the high-amplitude 1064 nm laser-induced PA signals indeed originated only from CTC absorption. 
The arterial and venous flow speeds of the CTC were calculated to be 0.33 mm/s and 0.20 mm/s, respectively, 
which are in general accordance with previously reported values28. A CTC cluster flowing in an artery was also 
imaged in vivo in a carotid artery cell injection experiment (Supplementary Fig. S2). No return of this CTC cluster 
was observed, which indicated that it might have been clogged at a vascular branching point, seeding a secondary 
tumor10.
Therapy results. To investigate the radiant energy required to kill a CTC, we used a single-shot 1064 nm 
laser pulse to irradiate cultured B16F10 melanoma cells in vitro. Different areas of a monolayer of melanoma 
cells were irradiated with increasing levels of laser fluence, and then the cells were stained with trypan blue to 
test cell viability (Supplementary Fig. S3). The results indicated that a 1064 nm laser pulse with 8.8 J/cm2 fluence 
was sufficient to guarantee cell death. Potential tissue damage by the therapy laser was also carefully investi-
gated. A monolayer of RBCs was imaged by phase contrast microscopy before and after 30 J/cm2 laser irradia-
tion (Supplementary Fig. S4). Comparison of the two images indicated no apparent change, with both showing 
donut-shaped morphology. In addition, measuring the optical absorbance of the supernatant showed no RBC 
hemolysis in blood samples exposed to 30 J/cm2 laser irradiation (Supplementary Fig. S5).
Therapy experiments were conducted in a similar manner to the imaging experiments. Figure 3 shows an 
event of single-CTC detection and real-time destruction. The CTC signal induced by the 1064 nm laser pulse 
immediately hardware-triggered a therapy laser pulse to irradiate the detected CTC with a 50 μ m focal diameter 
and a 25 J/cm2 fluence, above the lethal level. This lethal irradiation produced a PA signal with a much greater 
amplitude, ~14 times higher than the maximal imaging signal (Fig. 3c), and its peak location indicated that the 
CTC was within the focal spot of the therapy laser. This PA signal amplitude, measured in another experiment, 
was far higher than that of a regular blood vessel with the same irradiation (Supplementary Fig. S6). Therefore, 
we concluded that this PA signal mainly originated from light absorption by the CTC, and that this CTC was 
destroyed by the therapy laser irradiation. In total, four events of real-time expected photothermal killing of 
CTCs at different locations were recorded during 5 minutes in the experiment (Supplementary Movie S2–3). 
Flow cytography confirmed no disturbance to blood flow during 30 min of observation after this experiment. In 
addition, there were no visible damages on the mouse ear.
We also conducted a pseudo-therapy study to evaluate the performance of the system and demonstrate the 
value of this therapy scheme. Experiments were designed to mimic treating melanoma metastasis by imped-
ing CTC dissemination (Fig. 4a). First, cultured B16F10 cells were mixed with bovine blood and pumped into 
a translucent silicone tube to simulate CTCs. Then this mixture was pumped through our system to specifi-
cally detect and kill the CTCs (Supplementary Movie S4). For the control experiment, the therapy laser was 
turned off during the experiment, leaving the CTCs only imaged by our system. Next, the treated and untreated 
mixtures were subcutaneously inoculated into two groups of nude mice, respectively, simulating hematogenous 
metastases. Afterwards, the area around each inoculation site was imaged every week by acoustic resolution 
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(AR) PAM17,29 at 750 nm wavelength, to monitor tumor formation (Supplementary Fig. S7). After 30 days, only 
one of the six therapy experiments resulted in a tumor formation, and that tumor had a significantly slower 
growth, in comparison to the rapid tumor formation and growth following every control experiment (Fig. 4b,c, 
Supplementary Fig. S8). This only tumor from the therapy experiment could be attributed to the fact that the 
therapy laser (1 kHz maximum repetition rate) missed some CTCs that were detected within 1 ms after the last 
therapy laser shot (Supplementary Movie S4), which should not present a real problem since CTCs are more rare 
in vivo and the repetition rate of the therapy laser can be increased. The results indicated that our technique is 
capable of destroying CTCs with a high success rate, and that this therapy scheme is a promising way to impede 
metastasis for cancer therapy.
Discussion
We report both in vivo label-free imaging of melanoma CTCs using dual-wavelength PA flow cytography and 
on-the-spot pinpoint CTC destruction by nanosecond-pulsed NIR therapy laser irradiation. CTCs are important 
indicators of the severity of a tumor and the efficacy of tumor therapies1–3,5,8, making their reliable detection 
clinically significant. Because some CTCs are cloaked by platelets or coagulation factors, they are shielded from 
Figure 1. CTC imaging and destruction by dual-wavelength PA flow cytography combined with laser 
therapy. (a) Schematic of selected components of the experimental system. DM, dichroic mirror; MEMS, 
micro-electro-mechanical-system scanning mirror; OAC, optical-acoustic combiner; PBS, polarizing 
beamsplitter; UT, ultrasonic transducer. The 1064 nm and 532 nm imaging lasers are employed to image CTCs 
and vasculature, respectively. (b–e) Scheme of real-time detection and laser killing of CTCs. The CTC detector 
compares the earlier 1064 nm laser-induced CTC-specific PA signal against an optimized threshold level 
(purple dashed line in (b) and (c)) above the Hb signal, and thus can reliably distinguish CTCs and trigger 
the therapy laser (c). Within ~10 μ s, the therapy laser is fired and focused to the detected CTC location to 
photomechanically kill the CTC (e).
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many CTC detection agents as well as from the immune system3,8. However, our method does not suffer from this 
limitation because light can penetrate CTCs. This technique may be used clinically for non-invasive in vivo CTC 
Figure 2. Snapshots showing single CTCs travelling in vasculature. (a) 532 nm laser-induced (Top), 1064 nm 
laser-induced (Middle), and fused (Bottom) flow cytography images. In the 1064 nm laser-induced image, the 
white arrow and yellow square indicate the detected CTC; the red and blue dashed lines delineate the artery and 
vein boundaries, respectively. (b) Three fused snapshots spanning ~1 s, showing a single CTC traveling in the 
artery. (c) Three fused snapshots spanning ~2 s, showing a single CTC traveling in the vein. The times labeled in 
(b) and (c) are relative to CTC injection.
Figure 3. In vivo detection and expected photothermal killing of a CTC. The CTC was first detected in the 
1064 nm laser-induced flow cytography image (a) and then lethally irradiated by a therapy laser pulse, also at 
1064 nm, with a 50-μ m focal diameter (b). In (b), The much-higher-amplitude PA signal induced by the therapy 
laser pulse is illustrated by the filled yellow circle. (c) Profile of the PA signals from the region across the CTC, 
indicated by the dashed cyan line in (a). The x axis, parallel with the imaging laser’s scanning direction (from 
right to left), was centered at the CTC location. In the 1064 nm imaging laser-induced signals (red solid line), 
the CTC signal (shown in detail by the inset) had a contrast-to-noise-ratio of ~25. The therapy laser-induced 
PA signal’s peak location (dashed orange line) was only ~10 μ m away from the detected CTC location, which 
indicated that the CTC position (white cross in (b)) was within the therapy laser’s focal spot (circle in (b)).
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assays without labeling. In addition, many details about the process of tumor metastasis through CTCs are still 
unclear, and this high-resolution real-time CTC imaging technique can enable in vivo studies of CTC dynamics, 
such as monitoring tumor cells shedding from a primary tumor, invading nearby blood vessels, circulating in the 
vasculature, and extravasating from vascular walls.
Unlike therapeutics that use metastasis-specific features to direct the distribution of administered medication, 
the reported method works on a more selective “identify-then-locally-administer” basis. Because the radiant 
energy from the therapy laser is highly localized on the melanosomes within CTCs, other molecules in the CTCs, 
as well as adjacent RBCs, do not sustain damage. Moreover, our technology may have extra benefits in immu-
notherapy because it can help release viable tumor-specific antigens from lysed CTCs into vasculature, which 
can stimulate immune attacks on remaining CTCs as well as metastases, enhancing treatment efficacy30. Drug 
resistance from CTCs is also not an issue in our study because the destruction mechanism is completely physical.
Melanoma patients at all stages would potentially benefit from this technology if it were translated into the 
clinic successfully. For stages I and II, measuring CTC count could yield a more accurate diagnosis of a melano-
ma’s recurrence risks. For stage III, when there are CTCs in the bloodstream but no existing metastases, and stage 
IV, when there are CTCs in the bloodstream and existing metastases, the clearance of CTCs would potentially 
prevent metastasis. The immunoresponses induced by antigens released by lysed CTCs could potentially further 
treat any residual primary tumor as well as existing metastases.
In summary, using endogenous contrast, our system dynamically imaged rare single CTCs and CTC clus-
ters with single-cell resolution in vivo and performed real-time pinpoint photothermolysis of CTCs. The 
pseudo-therapy experiment demonstrated that our method can effectively kill CTCs in vasculature. This technol-
ogy works in a convenient reflection mode, and is translatable to clinics. It can serve as a bedside therapy device 
for cancer patients, which can improve their prognosis by early detection and destruction of CTCs. The technol-
ogy can also be applied for studying fundamental mechanisms of tumor metastasis through CTC dissemination.
Methods
All methods were performed in accordance with the guidelines of Washington University in St. Louis.
Dual-wavelength PA flow cytography. To induce PA signals, we employed a high-repetition-rate pico-
second laser (APL-4000–1064, Attodyne, Inc.; maximum pulse repetition rate: 500 kHz) to provide 6-ps laser 
pulses at 1064 nm and 532 nm wavelengths. After traveling a 25-meter delay line, the 532 nm laser beam was 
combined with the 1064 nm laser beam through a longpass dichroic mirror. Melanosome absorbs similarly to 
Hb at 532 nm, but > 10 times more strongly than Hb at 1064 nm, which provides a high CTC contrast against the 
RBC background. The combined laser beams were focused by a focusing lens, reflected by an optical-acoustic 
combiner (OAC), and directed to the target by a water-immersible MEMS (micro-electro-mechanical system) 
mirror for 1D fast scanning31,32. The target was mounted on a stepper-motor-driven translational stage to facilitate 
Figure 4. Scheme (a) and results (b,c) of the pseudo-therapy study. (a) The control experiment (bottom) was 
conducted after the therapy experiment (top) by simply switching off the therapy laser. The flow rate was set at 
~80 μ L/hr with ~20 CTCs flowing through the system every second. (b) Only 1 out of 6 therapy experiments 
had a tumor detected at week 3, compared to 100% tumor formation by week 1 in the control group. (c) 
Representative photos of the mice after experiments. (Left) No tumor was detected around the inoculation site 
(blue arrow) in 30 days following a therapy experiment. (Right) A raised tumor (blue arrow) was observed 10 
days after a control experiment.
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orthogonal slow axis scanning. The OAC comprised of an aluminum-coated prism and an uncoated prism, and 
the thin aluminum coating on the first prism reflected light but transmitted sound. A correction lens was attached 
to the top surface of the OAC to correct the optical aberration due to the prisms. Excited PA waves were also 
reflected by this MEMS mirror, collected by an acoustic lens, transmitted through the OAC, and detected by an 
ultrasonic transducer (V214-BB-RM, Olympus-NDT, Inc.). Since the 532 nm laser pulse traveled through the 
~80-ns delay line, the PA wave induced by the 532 nm laser pulse arrived ~80 ns later than that by the 1064 nm 
laser pulse (Fig. 1a). PA signals were then amplified by two radio-frequency amplifiers (ZX60-3018G-S+ and 
ZFL-500LN+ , Mini-circuits, Inc.) and acquired by a high-speed digitizer (ATS9350, Alazar Tech, Inc.). By steer-
ing both the optical and acoustic axes simultaneously, the system maintained confocal alignment over the entire 
FOV, providing high detection sensitivity. This flow cytography was capable of volumetric (3D) imaging at 10 Hz 
over a FOV of 3 × 0.25 mm2 at a depth up to ~0.7 mm, with a 3 μ m lateral resolution for the 532 nm flow cytog-
raphy images, 7 μ m for the 1064 nm flow cytography images, and ~26 μ m axial (depth) resolution for both. The 
length and width of the FOV can be tuned by varying the driving voltage of the MEMS mirror and by adjusting 
the scanning range of the stepper motor, respectively. It is also possible to achieve a higher frame rate at the 
expense of a larger scanning step size, as in Fig. 2, or of a shorter range for the stepper motor.
On-the-fly CTC detection. PA signals were concurrently analyzed for melanoma CTC detection based on 
the melanosome-specific 1064 nm absorption induced PA signals (Supplementary Fig. S1). The specially built 
CTC detector consisted of an ultrafast analog switch and a comparator (Supplementary Fig. S1). Based on the 
fixed 80-ns time interval between the 1064 nm and 532 nm laser pulses, a time window signal controlled the 
analog switch as a gate to selectively transmit the earlier 1064 nm laser-induced PA signal. The comparator com-
pared this gated PA signal with an optimized preset threshold voltage. A signal above the threshold indicated 
the presence of a melanoma CTC, and immediately triggered a high-pulse-energy therapy laser (INNOSLAB, 
EdgeWave, Inc.) to lethally irradiate the same CTC on the spot (Fig. 1c,d). Following a successful CTC detec-
tion, the detector was disabled for 1 ms to prevent double triggering by the much-higher-amplitude therapy 
laser-induced PA signal.
Real-time CTC destruction. Melanoma CTCs were irradiated by a high-pulse-energy 1064 nm laser pulse 
(7 ns) that could mechanically destroy the CTCs by explosive vaporization of the melanosomes inside26,27,33. The 
thermal diffusion distance during 7-ns laser exposure is ~30 nm, which means the thermal damage is confined to 
melanosomes, ~500 nm in diameter27. The therapy laser beam was coaxially aligned with the imaging laser beams 
by a polarizing beamsplitter and focused onto the CTC location. In order to maximize combining efficiency, a 
half-wave plate was used to adjust the polarization of the therapy laser beam. We optimized the focal spot size 
of the therapy laser based on the scanning speed of the MEMS mirror, the signal propagation and processing 
time, the CTC flow speed, and the therapy laser’s trigger-to-emission delay. The maximum scanning speed of the 
laser focal spot on the target was ~1 m/s. The acoustic flight time from the absorber to the ultrasonic transducer 
was ~10 μ s, while the signal processing time in the CTC detector circuits was ~30 ns and the trigger-delay time 
of the therapy laser was ~300 ns. Based on the blood flow speed, the CTC movement in blood vessel during the 
~10 μ s response time was negligible. In conclusion, the center of the therapy laser’s focal spot could be ~10 μ m 
(1 m/s × 10 μ s) away from the original imaged CTC location. Therefore, the focal spot of the therapy laser, with 
25 J/cm2 fluence, was adjusted to be 50 μ m in diameter to ensure coverage of the entire CTC with a sufficient local 
radiant intensity.
Experimental animals. Adult female ND4 Swiss Webster mice (Hsd: ND4, Envigo, Inc.; 20–25 g, 10–12 
weeks old) were used for the in vivo CTC imaging and laser killing experiment. The laboratory animal protocols 
were approved by the Animal Studies Committee of Washington University in St. Louis. Three days before the 
experiment, cannulation was performed to safely insert a catheter into the jugular vein or carotid artery of the 
mouse, and the hair on the mouse ear was removed with human hair-removing lotion. During the experiment, 
the mouse was maintained under anesthesia with 1.5% vaporized isoflurane, and taped to a lab-made animal 
holder, which was mounted on the stepper-motor-driven translation stage. Ultrasound gel was then applied to 
the imaging area to retain moisture and couple acoustic signals. A water tank filled with deionized water was 
then placed on top of the mouse ear. The membrane at the bottom of the water tank was in gentle contact with 
the ultrasound gel. During imaging, a 0.1-ml suspension containing ~106 B16F10 melanoma cells was injected 
through the cannulation catheter. The cells were cultured in DMEM supplemented with 10% fetal bovine serum 
at 37 °C in a humidified atmosphere with 5% CO2.
Female athymic nude mice (Hsd:Athymic Nude-Foxn1, Envigo, Inc.; 12–15 g, 3–4 weeks old) were used for 
the pseudo-therapy study. The laboratory animal protocols were approved by the Animal Studies Committee of 
Washington University in St. Louis. Before the study, the mice were randomly assigned into either the therapy 
group or the control group. In one experiment, a mixture was first prepared by diffusing cultured B16F10 mel-
anoma cells into bovine blood (Defibrinated Bovine Blood, Quad Five, Inc.). Next, this mixture was pumped in 
a translucent silicone tube (300 μ m inner diameter and 640 μ m outer diameter)—mimicking a blood vessel—
through our system with the therapy laser turned on. The flow rate was set at ~80 μ L/hr, with ~20 CTCs passing 
through the system every second. Afterwards, the cell mixture was reduced in volume by centrifugation to make a 
50 μ L dose (containing ~105 cells) that was subcutaneously inoculated into the dorsal area of a nude mouse in the 
therapy group. Then, another vial of mixture was acquired in a similar manner but with the therapy laser turned 
off, and a 50 μ L dose of this imaged (but not treated) mixture was inoculated into a nude mouse in the control 
group. Afterwards, all the mice were imaged by AR-PAM to detect tumor formation and to measure the volume of 
flat tumors, and raised tumors were measured using a caliper34. Mice were euthanized when the tumor dimension 
exceeded 2 cm or the tumor began to ulcerate.
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